Why most candidates fail
A drug starts as just a hopeful idea: a molecule that might bind a drug target linked to a disease. Out of thousands of molecules screened, only a handful look promising in a test tube, and far fewer survive what comes next. The honest truth is that roughly nine of every ten candidates that enter human testing never reach patients — they turn out to be unsafe, not effective enough, or impossible to manufacture reliably. This is not failure of effort; it is the system working. Each fallen candidate teaches us where biology surprised us.
Once a lead molecule is chosen, chemists tune it for the right mechanism of action, better absorption, and fewer toxic by-products. Sometimes the molecule given to a patient is a prodrug — inactive until the body converts it. All of this happens before a single human takes a dose.
The stages before humans
- Discovery & target validation — find a molecule that acts on a drug target and confirm that hitting that target should help the disease.
- Lab (preclinical) testing — cells and tissues in dishes show whether the molecule does what we hope and how it behaves chemically.
- Animal studies — at least two species are used to estimate a safe starting dose and to spot organ damage before any person is exposed.
- Regulatory go-ahead — only after this evidence may a company ask permission to begin a clinical trial in people.
Time, money, and honesty
From first idea to pharmacy shelf typically takes 10–15 years. The point of all this patience is evidence-based medicine: by the time you can be prescribed a drug, strangers have already taken it under careful watch so that the benefits and harms are known, not guessed. The later guides in this track walk through each human-testing phase, drug approval, and what happens once millions of people start using a medicine.